
NYSE:DOCS
This summary was created by AI, based on 1 opinions in the last 12 months.
Doximity (DOCS-N) has been under scrutiny following the latest reports from experts who express concern regarding its current valuation and recent performance. One reviewer highlights that the stock price appears to be prohibitively high compared to its recent financial results, which were disappointing. This sentiment suggests a sense of caution among investors, particularly as the last quarter did not meet expectations, raising questions about the company's growth outlook. The lack of enthusiasm in the reviews indicates that many see a need for Doximity to present stronger earnings or strategic adjustments before it can be considered a sound investment. Overall, there seems to be cautious sentiment surrounding Doximity's market position at this time.
DOCS has erased earlier gains from its last earnings report, amid the market drawdown, but it continues to be on a long-term uptrend, and forward sales and earnings estimates are strong. Analyst estimates have been trending higher in the past year, margins have been expanding, and it generates decent cash flows. It has a good balance sheet, but it is not cheap at 38X forward earnings. For a long-term investor, we would be comfortable holding here given its fundamental strength.
Unlock Premium - Try 5i Free
Up 38% since IPO in fall 2021. Shares got killed last year during inflation and rate hikes. Has since rebounded. It's been a round trip. Their last report was solid, but guidance was ugly, given a delay in their new telemedicine product given regulatory interference. But they've beaten every quarter. Pricey at 47x PE 2023 but are profitable.
Doximity is a American stock, trading under the symbol DOCS (previously DOCS-N on Stockchase) on the New York Stock Exchange (DOCS). It is usually referred to as NYSE:DOCS or DOCS
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on DOCS (previously DOCS-N on Stockchase). 0 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is . Read the latest stock experts' ratings for Doximity.
Doximity was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Doximity.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Doximity.
Doximity is covered by Stockchase experts and is worth watching.
On 2026-06-24, Doximity (DOCS) stock closed at a price of $20.83.
Is still too expensive. Their last quarter wasn't that good.